Sara Thompson

Sara Thompson is a Researcher at Yale University's Yale School of Medicine. Her work focuses on understanding the mechanisms of aneuploidy and its role in cancer progression, leveraging biochemical and pharmacological tools to explore therapeutic targets. She holds an MS degree and has contributed to studies on chromosomal instability, stress kinase signaling, and genome stability maintenance.

Research interests include the interplay between aneuploidy tolerance and oncogenic pathways, kinetochore-microtubule dynamics, and the application of synthetic inhibitors in cancer research. Her studies highlight how aneuploidy can act like oncogenes in driving tumor growth, offering new avenues for targeted therapies.

Recent work emphasizes the potential of anaphase catastrophe as a therapeutic strategy, particularly in lung cancer, by targeting cyclin E-Cdk2 complexes. Her findings also reveal p53's role in suppressing aneuploid cell proliferation and the regulatory networks governing ER localization of key proteins.

Despite her prolific research output, no specific grants, awards, or student advisement roles are documented in the provided text.